Hypocalcemia secondary to hypomagnesemia in a patient on liraglutide.
Ann Med Surg (Lond) · 2020
Last updated 2026-08-28| Journal | Ann Med Surg (Lond), 2020 |
|---|---|
| Citations | 4 |
| Relative citation ratio | 0.23 |
| NIH percentile | 15 |
| Molecules | liraglutide |
Abstract
A 73-year-old man with type 2 diabetes on Liraglutide with a history of coronary artery disease. Admitted to emergency for abdominal pain, severe diarrhea and episodes of tetany attacks. Laboratory workup reveals hypomagnesemia, hypocalcemia and normal parathormone (PTH). After intravenous administration of magnesium and calcium, the blood ionogram quickly normalized. In addition, plasma levels of intact parathyroid hormone increased immediately after magnesium administration. Strongly suggests that hypocalcemia resulted from a disruption of adequate parathyroid hormone secretion caused by hypomagnesemia which in turn was caused by severe diarrhea under treatment with Liraglutide.
Verbatim abstract via PubMed 33224484 ↗
Related research
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
- A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.
- Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study.
- Liraglutide and Renal Outcomes in Type 2 Diabetes.
- Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial.
- The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss.
- Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial.
- The Discovery and Development of Liraglutide and Semaglutide.